ArticleScientific reports2025
Breast microcalcifications as indicators of bone metastasis risk in early-stage breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cytokine Regulation of the Bone Pre- and Metastatic Niches: Implications for Breast Cancer Dormancy.Cells · 2026Review
- Mammography-Based Radiomics for Prediction of Nodal Status and Disease Burden in Breast Cancer: A Temporally Validated Study.Cancers · 2026Article
- Distinctive features of cancer-associated fibroblasts expressing CD105, a novel biomarker for bone metastasis, in early-stage invasive ductal breast cancer.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastasis is a leading cause of reduced survival in patients with advanced breast cancer. Therefore, identifying prognostic markers for bone metastasis at early disease stages is crucial. Microcalcifications are common findings in mammographic imaging and often serve as early diagnostic indicators. Certain types of microcalcifications have been linked to unfavorable genetic and molecular tumor profiles and are associated with poor prognosis. In particular, calcifications located within large ducts-such as casting-type, duct-centric patterns-have been described as independent markers of adverse outcome when compared to tumors with other calcification types or without calcifications. This study evaluated the prognostic significance of anarchic microcalcifications, defined as calcifications with irregular borders and/or disorganized patterns, in patients with early-stage breast cancer. Hematoxylin and eosin staining was used to assess the presence of these microcalcifications in invasive ductal carcinoma samples (n = 350). Their association with clinical and pathological characteristics was analyzed, including local relapse and bone metastasis occurrence. The presence of tumor microcalcifications was significantly associated with an increased risk of local relapse (p = 0.0360) and bone metastasis (p = 0.0020). Moreover, patients with microcalcifications exhibited shorter local relapse-free survival and bone metastasis-free survival (p = 0.0080 and p = 0.0020, respectively). Importantly, multivariate analysis confirmed that microcalcifications were an independent prognostic factor for both outcomes (p = 0.0150 and p = 0.0020, respectively). These findings suggest that the presence of tumor microcalcifications may serve as an independent prognostic marker for bone metastasis in early-stage breast cancer. Incorporating the evaluation of microcalcifications into routine pathological assessments could improve prognostic precision and support personalized treatment strategies. Further research is needed to elucidate the molecular mechanisms underlying the association between tumor microcalcifications and breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.